Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a
12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated
with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The
secondary objectives of this study in this study population are to assess the impact of DMF
over a 12-month period on patient-reported outcomes (PROs) and health economic-related
outcomes and to evaluate additional clinical outcomes at Month 12.